Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Fly Intel: Pre-market Movers » 09:02
06/24/20
06/24
09:02
06/24/20
09:02
IBIO

iBio

$1.46 /

+0.015 (+1.04%)

, DELL

Dell Technologies

$49.03 /

+0.675 (+1.40%)

, MAXR

Maxar Technologies

$16.47 /

+0.68 (+4.31%)

, AVAV

AeroVironment

$71.80 /

+2.12 (+3.04%)

, WGO

Winnebago

$70.84 /

-0.1 (-0.14%)

, EDIT

Editas Medicine

$34.42 /

+1.23 (+3.71%)

, CRTO

Criteo

$13.05 /

+0.69 (+5.58%)

, NOG

Northern Oil and Gas

$0.95 /

-0.0141 (-1.46%)

, VMW

VMware

$149.27 /

+1.265 (+0.85%)

, CCO

Clear Channel Outdoor

$1.19 /

+0.065 (+5.80%)

Check out this morning's…

Open Full Text

ShowHide Related Items >><<
WGO Winnebago
$70.84 /

-0.1 (-0.14%)

VMW VMware
$149.27 /

+1.265 (+0.85%)

NOG Northern Oil and Gas
$0.95 /

-0.0141 (-1.46%)

MAXR Maxar Technologies
$16.47 /

+0.68 (+4.31%)

IBIO iBio
$1.46 /

+0.015 (+1.04%)

EDIT Editas Medicine
$34.42 /

+1.23 (+3.71%)

DELL Dell Technologies
$49.03 /

+0.675 (+1.40%)

CRTO Criteo
$13.05 /

+0.69 (+5.58%)

CCO Clear Channel Outdoor
$1.19 /

+0.065 (+5.80%)

AVAV AeroVironment
$71.80 /

+2.12 (+3.04%)

IBIO iBio
$1.46 /

+0.015 (+1.04%)

DELL Dell Technologies
$49.03 /

+0.675 (+1.40%)

06/24/20 Wells Fargo
Dell Technologies price target raised to $70 from $57 at Wells Fargo
06/24/20 BofA
Dell most likely to partially monetize VMware stake but keep control, says BofA
06/24/20 Morgan Stanley
Morgan Stanley says recent Dell comments suggest most likely path is current one
06/24/20 Mizuho
VMware investors should approach Dell story with caution, says Mizuho
MAXR Maxar Technologies
$16.47 /

+0.68 (+4.31%)

06/24/20 JPMorgan
Maxar Technologies price target raised to $20 from $16 at JPMorgan
01/15/20 Credit Suisse
Maxar Technologies upgraded to Neutral from Underperform at Credit Suisse
01/08/20 JPMorgan
Maxar Technologies price target raised to $25 from $15 at JPMorgan
12/30/19 Raymond James
Maxar Technologies downgraded to Market Perform from Outperform at Raymond James
AVAV AeroVironment
$71.80 /

+2.12 (+3.04%)

06/24/20 Baird
AeroVironment price target raised to $86 from $71 at Baird
06/24/20 Canaccord
AeroVironment price target raised to $84 from $75 at Canaccord
06/24/20 Piper Sandler
AeroVironment price target raised to $93 from $76 at Piper Sandler
06/18/20 Canaccord
AeroVironment should meet is 2020 guidance, says Canaccord
WGO Winnebago
$70.84 /

-0.1 (-0.14%)

06/24/20 CL King
Winnebago Q3 loss much lower than feared, says CL King
05/29/20 Sidoti
Winnebago downgraded to Neutral on valuation at Sidoti
05/29/20
Fly Intel: Top five analyst downgrades
05/29/20 Sidoti
Winnebago downgraded to Neutral from Buy at Sidoti
EDIT Editas Medicine
$34.42 /

+1.23 (+3.71%)

06/18/20 SunTrust
Editas Medicine initiated with a Buy at SunTrust
02/27/20 Raymond James
Editas Medicine price target lowered to $41 from $44 at Raymond James
02/21/20 Wells Fargo
Editas Medicine initiated with an Equal Weight at Wells Fargo
02/03/20 Evercore ISI
Evercore ISI downgrades Crispr Therapeutics, questions relative valuation
CRTO Criteo
$13.05 /

+0.69 (+5.58%)

06/24/20 BMO Capital
Criteo downgraded to Market Perform from Outperform at BMO Capital
05/08/20 Deutsche Bank
Criteo price target lowered to $16 from $22 at Deutsche Bank
05/05/20 SunTrust
Criteo price target lowered to $13 from $25 at SunTrust
04/20/20 Nomura Instinet
Criteo price target lowered to $10 from $14 at Nomura Instinet
NOG Northern Oil and Gas
$0.95 /

-0.0141 (-1.46%)

03/09/20 SunTrust
Northern Oil and Gas downgraded to Hold from Buy at SunTrust
01/03/20 Northland
Northern Oil and Gas is a 2020 Top Pick at Northland
12/20/19 Imperial Capital
Northern Oil and Gas upgraded to Outperform from In-Line at Imperial Capital
VMW VMware
$149.27 /

+1.265 (+0.85%)

06/24/20 Goldman Sachs
VMware price target raised to $158 from $143 at Goldman Sachs
CCO Clear Channel Outdoor
$1.19 /

+0.065 (+5.80%)

06/24/20 Citi
Clear Channel Outdoor upgraded to Buy from Neutral at Citi
06/16/20 Cowen
Clear Channel Outdoor price target raised to $2.20 from $1.50 at Cowen
04/01/20 Barrington
Clear Channel Outdoor downgraded to Market Perform from Outperform at Barrington
02/03/20
Fly Intel: Top five analyst initiations
WGO Winnebago
$70.84 /

-0.1 (-0.14%)

VMW VMware
$149.27 /

+1.265 (+0.85%)

NOG Northern Oil and Gas
$0.95 /

-0.0141 (-1.46%)

MAXR Maxar Technologies
$16.47 /

+0.68 (+4.31%)

IBIO iBio
$1.46 /

+0.015 (+1.04%)

EDIT Editas Medicine
$34.42 /

+1.23 (+3.71%)

DELL Dell Technologies
$49.03 /

+0.675 (+1.40%)

CRTO Criteo
$13.05 /

+0.69 (+5.58%)

CCO Clear Channel Outdoor
$1.19 /

+0.065 (+5.80%)

AVAV AeroVironment
$71.80 /

+2.12 (+3.04%)

  • 24
    Jun
WGO Winnebago
$70.84 /

-0.1 (-0.14%)

VMW VMware
$149.27 /

+1.265 (+0.85%)

IBIO iBio
$1.46 /

+0.015 (+1.04%)

DELL Dell Technologies
$49.03 /

+0.675 (+1.40%)

AVAV AeroVironment
$71.80 /

+2.12 (+3.04%)

VMW VMware
$149.27 /

+1.265 (+0.85%)

NOG Northern Oil and Gas
$0.95 /

-0.0141 (-1.46%)

MAXR Maxar Technologies
$16.47 /

+0.68 (+4.31%)

IBIO iBio
$1.46 /

+0.015 (+1.04%)

DELL Dell Technologies
$49.03 /

+0.675 (+1.40%)

CRTO Criteo
$13.05 /

+0.69 (+5.58%)

CCO Clear Channel Outdoor
$1.19 /

+0.065 (+5.80%)

VMW VMware
$149.27 /

+1.265 (+0.85%)

MAXR Maxar Technologies
$16.47 /

+0.68 (+4.31%)

DELL Dell Technologies
$49.03 /

+0.675 (+1.40%)

AVAV AeroVironment
$71.80 /

+2.12 (+3.04%)

Syndicate
Editas Medicine 6M share Spot Secondary priced at $31.25 » 06:08
06/24/20
06/24
06:08
06/24/20
06:08
EDIT

Editas Medicine

$34.42 /

+1.23 (+3.71%)

The deal size was…

The deal size was increased to 6M shares of common stock from 4M shares of common stock and the range was $31.00-$32.00. Morgan Stanley acted as sole book running manager for the offering.

ShowHide Related Items >><<
EDIT Editas Medicine
$34.42 /

+1.23 (+3.71%)

EDIT Editas Medicine
$34.42 /

+1.23 (+3.71%)

06/18/20 SunTrust
Editas Medicine initiated with a Buy at SunTrust
02/27/20 Raymond James
Editas Medicine price target lowered to $41 from $44 at Raymond James
02/21/20 Wells Fargo
Editas Medicine initiated with an Equal Weight at Wells Fargo
02/03/20 Evercore ISI
Evercore ISI downgrades Crispr Therapeutics, questions relative valuation
EDIT Editas Medicine
$34.42 /

+1.23 (+3.71%)

  • 24
    Jun
EDIT Editas Medicine
$34.42 /

+1.23 (+3.71%)

On The Fly
Fly Intel: After-Hours Movers » 19:02
06/23/20
06/23
19:02
06/23/20
19:02
AVAV

AeroVironment

$71.80 /

+2.12 (+3.04%)

, LZB

La-Z-Boy

$27.82 /

+0.26 (+0.94%)

, DELL

Dell Technologies

$49.03 /

+0.675 (+1.40%)

, VMW

VMware

$149.27 /

+1.265 (+0.85%)

, MAXR

Maxar Technologies

$16.47 /

+0.68 (+4.31%)

, REGI

Renewable Energy

$28.57 /

+0.52 (+1.85%)

, TELA

Tela Bio

$20.85 /

-0.08 (-0.38%)

, EDIT

Editas Medicine

$34.42 /

+1.23 (+3.71%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
VMW VMware
$149.27 /

+1.265 (+0.85%)

TELA Tela Bio
$20.85 /

-0.08 (-0.38%)

REGI Renewable Energy
$28.57 /

+0.52 (+1.85%)

MAXR Maxar Technologies
$16.47 /

+0.68 (+4.31%)

LZB La-Z-Boy
$27.82 /

+0.26 (+0.94%)

EDIT Editas Medicine
$34.42 /

+1.23 (+3.71%)

DELL Dell Technologies
$49.03 /

+0.675 (+1.40%)

AVAV AeroVironment
$71.80 /

+2.12 (+3.04%)

AVAV AeroVironment
$71.80 /

+2.12 (+3.04%)

06/18/20 Canaccord
AeroVironment should meet is 2020 guidance, says Canaccord
05/15/20 Piper Sandler
AeroVironment largest ever contract brings visibility, says Piper Sandler
03/04/20 Baird
AeroVironment price target lowered to $71 from $81 at Baird
03/04/20 Canaccord
AeroVironment price target lowered to $75 from $80 at Canaccord
LZB La-Z-Boy
$27.82 /

+0.26 (+0.94%)

04/13/20 Sidoti
La-Z-Boy downgraded to Neutral from Buy at Sidoti
03/09/20 Sidoti
La-Z-Boy upgraded to Buy from Neutral at Sidoti
02/20/20
Fly Intel: Top five analyst upgrades
02/20/20 Stifel
La-Z-Boy upgraded to Buy from Hold at Stifel
DELL Dell Technologies
$49.03 /

+0.675 (+1.40%)

05/29/20 RBC Capital
Dell Technologies price target raised to $48 from $42 at RBC Capital
05/27/20 BMO Capital
VMware price target lowered to $152 from $163 at BMO Capital
05/26/20 Deutsche Bank
Dell Technologies price target lowered to $52 from $56 at Deutsche Bank
05/19/20 Barclays
Barclays lowers estimates in IT hardware after April survey
VMW VMware
$149.27 /

+1.265 (+0.85%)

05/29/20 KeyBanc
VMware price target raised to $170 from $160 at KeyBanc
05/29/20 Morgan Stanley
VMware price target raised to $149 from $136 at Morgan Stanley
05/29/20 RBC Capital
VMware price target raised to $181 from $165 at RBC Capital
05/29/20 Mizuho
VMware price target raised to $152 from $140 at Mizuho
MAXR Maxar Technologies
$16.47 /

+0.68 (+4.31%)

01/15/20 Credit Suisse
Maxar Technologies upgraded to Neutral from Underperform at Credit Suisse
01/08/20 JPMorgan
Maxar Technologies price target raised to $25 from $15 at JPMorgan
12/30/19 Raymond James
Maxar Technologies downgraded to Market Perform from Outperform at Raymond James
12/19/19 CIBC
Maxar Technologies upgraded to Neutral from Underperformer at CIBC
REGI Renewable Energy
$28.57 /

+0.52 (+1.85%)

05/28/20 Canaccord
Renewable Energy price target raised to $44 from $34 at Canaccord
01/21/20 Roth Capital
Roth Capital positive on Renewable Energy after ending of Philips 66 pact
01/03/20 Roth Capital
Renewable Energy price target raised to $33 from $22 at Roth Capital
01/03/20 Piper Sandler
Renewable Energy price target raised to $41 from $32 at Piper Jaffray
TELA Tela Bio
$20.85 /

-0.08 (-0.38%)

06/18/20 JMP Securities
Tela Bio price target raised to $24 from $20 at JMP Securities
06/10/20 Canaccord
Tela Bio price target raised to $20 from $15 at Canaccord
03/27/20 Piper Sandler
Demand for Tela Bio's OviTex/Hernia PRS 'encouraging,' says Piper Sandler
03/03/20 Piper Sandler
Piper recommends three Med Tech names amid coronavirus selloff
EDIT Editas Medicine
$34.42 /

+1.23 (+3.71%)

06/18/20 SunTrust
Editas Medicine initiated with a Buy at SunTrust
02/27/20 Raymond James
Editas Medicine price target lowered to $41 from $44 at Raymond James
02/21/20 Wells Fargo
Editas Medicine initiated with an Equal Weight at Wells Fargo
02/03/20 Evercore ISI
Evercore ISI downgrades Crispr Therapeutics, questions relative valuation
VMW VMware
$149.27 /

+1.265 (+0.85%)

TELA Tela Bio
$20.85 /

-0.08 (-0.38%)

REGI Renewable Energy
$28.57 /

+0.52 (+1.85%)

MAXR Maxar Technologies
$16.47 /

+0.68 (+4.31%)

LZB La-Z-Boy
$27.82 /

+0.26 (+0.94%)

EDIT Editas Medicine
$34.42 /

+1.23 (+3.71%)

DELL Dell Technologies
$49.03 /

+0.675 (+1.40%)

AVAV AeroVironment
$71.80 /

+2.12 (+3.04%)

  • 24
    Jun
  • 26
    Jun
VMW VMware
$149.27 /

+1.265 (+0.85%)

DELL Dell Technologies
$49.03 /

+0.675 (+1.40%)

AVAV AeroVironment
$71.80 /

+2.12 (+3.04%)

VMW VMware
$149.27 /

+1.265 (+0.85%)

MAXR Maxar Technologies
$16.47 /

+0.68 (+4.31%)

DELL Dell Technologies
$49.03 /

+0.675 (+1.40%)

VMW VMware
$149.27 /

+1.265 (+0.85%)

MAXR Maxar Technologies
$16.47 /

+0.68 (+4.31%)

LZB La-Z-Boy
$27.82 /

+0.26 (+0.94%)

DELL Dell Technologies
$49.03 /

+0.675 (+1.40%)

AVAV AeroVironment
$71.80 /

+2.12 (+3.04%)

Syndicate
Editas Medicine announces offering of 4M shares of common stock » 16:29
06/23/20
06/23
16:29
06/23/20
16:29
EDIT

Editas Medicine

$34.34 /

+1.15 (+3.46%)

Editas Medicine announced…

Editas Medicine announced that it intends to offer and sell 4M shares of its common stock in an underwritten public offering. Morgan Stanley is acting as sole book-running manager for the offering.

ShowHide Related Items >><<
EDIT Editas Medicine
$34.34 /

+1.15 (+3.46%)

EDIT Editas Medicine
$34.34 /

+1.15 (+3.46%)

06/18/20 SunTrust
Editas Medicine initiated with a Buy at SunTrust
02/27/20 Raymond James
Editas Medicine price target lowered to $41 from $44 at Raymond James
02/21/20 Wells Fargo
Editas Medicine initiated with an Equal Weight at Wells Fargo
02/03/20 Evercore ISI
Evercore ISI downgrades Crispr Therapeutics, questions relative valuation
EDIT Editas Medicine
$34.34 /

+1.15 (+3.46%)

Syndicate
Editas Medicine files to sell 4M shares of common stock  16:15
06/23/20
06/23
16:15
06/23/20
16:15
EDIT

Editas Medicine

$34.34 /

+1.15 (+3.46%)

 
ShowHide Related Items >><<
EDIT Editas Medicine
$34.34 /

+1.15 (+3.46%)

EDIT Editas Medicine
$34.34 /

+1.15 (+3.46%)

06/18/20 SunTrust
Editas Medicine initiated with a Buy at SunTrust
02/27/20 Raymond James
Editas Medicine price target lowered to $41 from $44 at Raymond James
02/21/20 Wells Fargo
Editas Medicine initiated with an Equal Weight at Wells Fargo
02/03/20 Evercore ISI
Evercore ISI downgrades Crispr Therapeutics, questions relative valuation
EDIT Editas Medicine
$34.34 /

+1.15 (+3.46%)

Initiation
Editas Medicine initiated with a Buy at SunTrust » 07:08
06/18/20
06/18
07:08
06/18/20
07:08
EDIT

Editas Medicine

$29.88 /

-0.99 (-3.21%)

, ABBV

AbbVie

$95.76 /

-0.4 (-0.42%)

SunTrust analyst Joon Lee…

SunTrust analyst Joon Lee initiated coverage of Editas Medicine (EDIT) with a Buy rating and $45 price target. The company's "first and the only" in vivo genome editing program is progressing with platform validation on the horizon, the analyst tells investors in a research note, adding that a positive trial update for EDIT-101 coming as soon as the second half of 2020 would be a "positive readthrough for additional genetic blindness indications". Partnering with AbbVie (ABBV) with up to $1B in milestones for ophthalmologic indications is also "de-risking clinical development and commercialization", Joon Lee states.

ShowHide Related Items >><<
EDIT Editas Medicine
$29.88 /

-0.99 (-3.21%)

ABBV AbbVie
$95.76 /

-0.4 (-0.42%)

EDIT Editas Medicine
$29.88 /

-0.99 (-3.21%)

02/27/20 Raymond James
Editas Medicine price target lowered to $41 from $44 at Raymond James
02/21/20 Wells Fargo
Editas Medicine initiated with an Equal Weight at Wells Fargo
02/03/20 Evercore ISI
Evercore ISI downgrades Crispr Therapeutics, questions relative valuation
12/03/19 Raymond James
Audentes downgraded to Market Perform from Outperform at Raymond James
ABBV AbbVie
$95.76 /

-0.4 (-0.42%)

06/17/20 UBS
AbbVie price target raised to $109 from $96 at UBS
06/11/20 Guggenheim
Genmab deal with AbbVie topped high expectations, says Guggenheim
06/11/20 SunTrust
Genmab price target raised to $39 from $36 at SunTrust
06/11/20 H.C. Wainwright
Genmab price target raised to $40 from $34 at H.C. Wainwright
EDIT Editas Medicine
$29.88 /

-0.99 (-3.21%)

ABBV AbbVie
$95.76 /

-0.4 (-0.42%)

ABBV AbbVie
$95.76 /

-0.4 (-0.42%)

ABBV AbbVie
$95.76 /

-0.4 (-0.42%)

ABBV AbbVie
$95.76 /

-0.4 (-0.42%)

Hot Stocks
Editas Medicine presents pre-clinical data from study of EDIT-301 » 06:05
06/12/20
06/12
06:05
06/12/20
06:05
EDIT

Editas Medicine

$25.00 /

-2.5 (-9.09%)

Editas Medicine announced…

Editas Medicine announced results from a pre-clinical, proof-of-concept study of EDIT-301. EDIT-301 is being developed as a potentially best-in-class, durable medicine to treat sickle cell disease. EDIT-301 contains CD34+ hematopoietic stem cells from sickle patients that are edited at the HBG1/2 promoter in the beta-globin locus using Cas12a to induce fetal hemoglobin where HbF-inducing mutations occur naturally. The company reported the data at the 25th Congress of the European Hematology Association being held virtually. In vitro studies with EDIT-301 revealed several desirable properties. In particular, editing was highly efficient and reproducible, with approximately 90% editing in multiple sickle patient donors. Further, EDIT-301 derived red blood cells had more than 50% HbF expression. Finally, EDIT-301 derived red blood cells had a significant improvement in deformability, which could aid red blood cell transit without sickling, and a four-fold decrease in sickling, when subjected to reduced oxygen levels compared to unedited control cells. These data suggest EDIT-301 can provide potential clinical benefit for sickle patients. In vivo studies with EDIT-301 revealed desirable properties. In particular, editing was highly efficient with greater than 90% editing in bone marrow cells from mice infused with edited CD34+ cells 16 weeks post infusion. Further, HbF expression was increased by approximately 50% in the red blood cells derived from these edited cells. Finally, approximately 90% of these cells were HbF positive, demonstrating that HbF expression was pan-cellular, a likely critical property for potential clinical benefit.

ShowHide Related Items >><<
EDIT Editas Medicine
$25.00 /

-2.5 (-9.09%)

EDIT Editas Medicine
$25.00 /

-2.5 (-9.09%)

02/27/20 Raymond James
Editas Medicine price target lowered to $41 from $44 at Raymond James
02/21/20 Wells Fargo
Editas Medicine initiated with an Equal Weight at Wells Fargo
02/03/20 Evercore ISI
Evercore ISI downgrades Crispr Therapeutics, questions relative valuation
12/03/19 Raymond James
Audentes downgraded to Market Perform from Outperform at Raymond James
EDIT Editas Medicine
$25.00 /

-2.5 (-9.09%)

Over a month ago
Hot Stocks
Editas Medicine presents preclinical data on CRISPR-Cas12a » 09:22
05/15/20
05/15
09:22
05/15/20
09:22
EDIT

Editas Medicine

$24.30 /

-0.21 (-0.86%)

Editas Medicine announced…

Editas Medicine announced results from a pre-clinical study evaluating multi-gene knockout and transgene knock-in using its proprietary engineered CRISPR-Cas12a in induced pluripotent stem cells for the development of engineered cell immunotherapy medicines. The results of this study further reinforce Editas Medicine's belief in the transformative potential of iPSC-derived natural killer cells as off-the-shelf engineered cell medicines for the treatment of solid tumor cancers. The Company reported these data today in an oral presentation at the 23rd Annual Meeting of the American Society of Gene & Cell Therapy being held virtually. Induced pluripotent stem cells offer a renewable source of highly characterized cells that can be differentiated into an array of immune effector cells, including, but not limited to, iPSC-derived natural killer cells. Edited iPSC clones can then be screened and selected to contain only the desired edits, ensuring a pure and edited final population of iNKs. Allogenic NK cells are an effective cancer cell therapy without evidence of graft versus host disease. In this study, CRISPR-Cas12a was used to make highly edited iPSC clones. The iPSCs were then differentiated into functional iNK cells. The iNKs derived from the edited iPSC clones had enhanced tumor killing activity relative to iNKs from unedited iPSCs, demonstrating the utility of an edited iPSC platform. This data supports the continued development of off-the-shelf engineered cell medicines for people with solid tumor cancers. Editas Medicine is also advancing programs using CRISPR editing for the potential treatment of both solid and liquid tumors. The Company initiated IND-enabling studies for EDIT-201, a healthy donor NK engineered cell medicine for solid tumors and is advancing its engineered gamma-delta T cell program. In addition, the Company is advancing oncology therapies with engineered alpha-beta T cells in collaboration with Bristol Myers Squibb.

ShowHide Related Items >><<
EDIT Editas Medicine
$24.30 /

-0.21 (-0.86%)

EDIT Editas Medicine
$24.30 /

-0.21 (-0.86%)

02/27/20 Raymond James
Editas Medicine price target lowered to $41 from $44 at Raymond James
02/21/20 Wells Fargo
Editas Medicine initiated with an Equal Weight at Wells Fargo
02/03/20 Evercore ISI
Evercore ISI downgrades Crispr Therapeutics, questions relative valuation
12/03/19 Raymond James
Audentes downgraded to Market Perform from Outperform at Raymond James
EDIT Editas Medicine
$24.30 /

-0.21 (-0.86%)

Hot Stocks
Editas Medicine announces programs outlook » 07:37
05/07/20
05/07
07:37
05/07/20
07:37
EDIT

Editas Medicine

$24.99 /

-0.62 (-2.42%)

In Vivo CRISPR Medicines:…

In Vivo CRISPR Medicines: EDIT-101 for LCA10: First in vivo CRISPR medicine administered to a patient; Editas Medicine and Allergan announced the treatment of the first patient in the BRILLIANCE Phase 1/2 clinical trial of EDIT-101 at Oregon Health & Science University Casey Eye Institute, a world-recognized academic eye center. The study has been cleared to continue based on a review of safety data on the first patient. The Company plans to complete dosing of the adult low-dose cohort and to dose at least one patient of the adult mid-dose cohort by the end of 2020. EDIT-102 for Usher Syndrome 2: Ready for IND-enabling studies pending Allergan option exercise; Under the terms of its 2017 alliance agreement with Allergan, Editas Medicine has delivered a preclinical data package to Allergan for potential licensing. EDIT-102 is ready for IND-enabling studies pending Allergan's option exercise. A decision is expected by the third quarter of 2020. Autosomal Dominant Retinitis Pigmentosa 4: Nomination of development candidate delayed to 2021. Due to interruptions from the COVID-19 outbreak, Editas Medicine is delaying to 2021 the declaration of a development candidate for an experimental medicine to treat autosomal dominant retinitis pigmentosa 4. Engineered Cell Medicines: EDIT-301 for Sickle Cell Disease and Beta-Thalassemia: IND filing expected by end of 2020. Editas Medicine is developing EDIT-301 using Cas12a (Cpf1), a proprietary enzyme, as a potentially best-in-class medicine to treat sickle cell disease and beta-thalassemia. Preclinical in vivo toxicology studies are in progress and the Company expects to file an IND for sickle cell disease by the end of 2020. EDIT-201 to Treat Solid Tumors: Declared candidate and initiated IND-enabling studies for allogeneic NK cell medicine: EDIT-201 is an allogeneic healthy-donor natural killer (NK) cell medicine for the treatment of solid tumors. Editas Medicine plans to present preclinical data on EDIT-201 at a scientific conference in the second half of 2020.

ShowHide Related Items >><<
EDIT Editas Medicine
$24.99 /

-0.62 (-2.42%)

02/27/20 Raymond James
Editas Medicine price target lowered to $41 from $44 at Raymond James
02/21/20 Wells Fargo
Editas Medicine initiated with an Equal Weight at Wells Fargo
02/03/20 Evercore ISI
Evercore ISI downgrades Crispr Therapeutics, questions relative valuation
12/03/19 Raymond James
Audentes downgraded to Market Perform from Outperform at Raymond James
Hot Stocks
Editas Medicine expects cash to fund operating expenses for next 24 months » 07:35
05/07/20
05/07
07:35
05/07/20
07:35
EDIT

Editas Medicine

$24.99 /

-0.62 (-2.42%)

The Company expects that…

The Company expects that its existing cash, cash equivalents and marketable securities of $415.0 million at March 31, 2020, and anticipated interest income will enable it to fund its operating expenses and capital expenditures for at least the next 24 months. The Company remains committed to diligently managing expenses to maintain a strong balance sheet moving forward.

ShowHide Related Items >><<
EDIT Editas Medicine
$24.99 /

-0.62 (-2.42%)

02/27/20 Raymond James
Editas Medicine price target lowered to $41 from $44 at Raymond James
02/21/20 Wells Fargo
Editas Medicine initiated with an Equal Weight at Wells Fargo
02/03/20 Evercore ISI
Evercore ISI downgrades Crispr Therapeutics, questions relative valuation
12/03/19 Raymond James
Audentes downgraded to Market Perform from Outperform at Raymond James

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.